CStone Pharmaceuticals’ exclusive collaboration and license agreement with Blueprint Medicines

Cooley advised CStone Pharmaceuticals on its exclusive collaboration and license agreement with Blueprint Medicines to develop and commercialize its cancer therapy, avapritnib, in mainland China, Hong…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Michael Patrini

This content is for Standard 1 Year members only.
Login Join Now